Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms

Introduction

Myeloproliferative neoplasms (MPNs) are defined by clonal proliferation of hematopoietic stem cells leading to uncontrolled proliferation of mature myeloid cells, which are hypersensitive to cytokine stimulation for proliferation, cell survival, and differentiation.[1] The incidence of MPNs is 2.3 to 2.8 per 100,000 persons/year and it is primarily a disease of elderly and slightly more common in males.[2] All the entities have distinguishing features based on affected cell lines and fibrosis in the bone marrow compartment.[3]

Authors' Contributions

M.S. was involved in writing–original draft and data curation. A.H.L.P. contributed to conceptualization, resources, and writing of the original draft.

Publication History

Article published online:
27 November 2023

• References

• 1 Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 2017; 129 (06) 680-692
• 2 Iurlo A, Cattaneo D, Bucelli C, Baldini L. New perspectives on polycythemia vera: from diagnosis to therapy. Int J Mol Sci 2020; 21 (16) 5805
• 3 Dixith R, Sara A, Vangala N. et al. Clinicopathological spectrum of BCR:ABL-negative myeloproliferative neoplasms with correlation with Janus-associated kinase 2 mutation. Indian J Med Paediatr Oncol 2019; 40 (01) 35-40
• 4 DePalma L, Delgado P, Werner M. Diagnostic discrimination and cost-effective assay strategy for leukocyte alkaline phosphatase. Clin Chim Acta 1996; 244 (01) 83-90
• 5 Khoury JD, Solary E, Abla O. et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022; 36 (07) 1703-1719
• 6 Maddali M, Kulkarni UP, Ravindra N. et al. Mutation profile in BCR:ABL1-negative myeloproliferative neoplasms: a single-center experience from India. Hematol Oncol Stem Cell Ther 2021
• 7 Rabade N, Subramanian PG, Kodgule R. et al. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India. Indian J Pathol Microbiol 2018; 61 (02) 209-213
• 8 Mughal TI, Gotlib J, Mesa R. et al. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. Leuk Res 2018; 67: 67-74
• 9 Polyatskin IL, Artemyeva AS, Krivolapov YA. [Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition):lymphoid tumors]. Arkh Patol 2019; 81 (03) 59-65
• 10 Kim J, Byun JM, Hong J. et al. Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms. Sci Rep 2021; 11 (01) 17819
• 11 Rumi E, Boveri E, Bellini M. et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget 2017; 8 (60) 101735-101744
• 12 Arachchillage DJ, Mackillop L, Chandratheva A, Motawani J, MacCallum P, Laffan M. Guidelines for thrombophilia testing: A British Society for Haematology guideline. Br J Haematol 2022
• 13 Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 2017; 129 (06) 667-679
• 14 Behnert A, Meyer J, Parsa JY. et al. Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples. Leukemia 2022; 36 (01) 279-282
• 15 Wang SA, Hasserjian RP, Tam W. et al. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica 2017; 102 (08) 1352-1360
• 16 Thiele J, Kvasnicka HM, Müllauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011; 117 (21) 5710-5718
• 17 Patnaik MM, Timm MM, Vallapureddy R. et al. Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer J 2017; 7 (07) e584
• 18 Marcellino B, El Jamal SM, Mascarenhas JO. Distinguishing autoimmune myelofibrosis from primary myelofibrosis. Clin Adv Hematol Oncol 2018; 16 (09) 619-626
• 19 Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol 2008; 87 (01) 1-10
• 20 Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 2021; 96 (01) 145-162
• 21 Carobbio A, Finazzi G, Antonioli E. et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 2009; 37 (09) 1016-1021
• 22 Takahashi K, Patel KP, Kantarjian H. et al. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood 2013; 122 (23) 3784-3786
• 23 Park SH, Chi HS, Cho YU, Jang S, Park CJ. The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasm. Blood Res 2013; 48 (02) 128-132